Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $30.72 USD
Change Today +0.11 / 0.36%
Volume 309.1K
PODD On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

insulet corp (PODD) Snapshot

Open
$30.68
Previous Close
$30.61
Day High
$30.97
Day Low
$30.24
52 Week High
12/8/14 - $47.97
52 Week Low
01/15/15 - $27.02
Market Cap
1.7B
Average Volume 10 Days
630.8K
EPS TTM
$-0.58
Shares Outstanding
56.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INSULET CORP (PODD)

insulet corp (PODD) Related Bloomberg News

View More Bloomberg News

insulet corp (PODD) Related Businessweek News

No Related Businessweek News Found

insulet corp (PODD) Details

Insulet Corporation develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. The company offers OmniPod Insulin Management System (OmniPod System), which consists of the OmniPod, a disposable insulin infusion device that integrates an infusion set, automated cannula insertion, insulin reservoir, drive mechanism, and batteries; and personal diabetes manager, a handheld wireless device. It also sells blood glucose testing supplies, insulin pumps, pump supplies, pharmaceuticals, and other products for the management and treatment of diabetes. The company sells and markets its OmniPod System to diabetes practitioners, academic medical centers, clinics, people with insulin-dependent diabetes, third-party payors, and government agencies, as well as third-party distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.

519 Employees
Last Reported Date: 02/26/15
Founded in 2000

insulet corp (PODD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $182.5K
Chief Financial Officer
Total Annual Compensation: $242.6K
Chief Operating Officer
Total Annual Compensation: $453.4K
Director of Advanced Technology and Director
Total Annual Compensation: $376.9K
General Counsel and Secretary
Total Annual Compensation: $265.0K
Compensation as of Fiscal Year 2014.

insulet corp (PODD) Key Developments

Insulet Corporation Announces Executive Changes, Effective from May 4

Insulet Corporation appointed Michael Levitz as chief financial officer starting May 4. Mike will succeed Allison Dorval, who has announced her resignation, effective May 4, to pursue other professional opportunities and will remain with Insulet through July 3, to assist with an effective transition. Levitz brings more than 15 years of public company financial experience to Insulet. He is currently the Senior Vice President, Chief Financial Officer and Treasurer of Analogic Corp.

Insulet Corporation Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-02-2015 04:00 PM

Insulet Corporation Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-02-2015 04:00 PM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, FL 32837, United States.

Insulet Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter of 2015 and Year Ending December 31, 2015

Insulet Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue of $72,561,000 compared to $68,533,000 a year ago. Operating loss was $2,255,000 compared to operating profit of $206,000 a year ago. This result was primarily driven by a 19% increase in operating expenses to $38.9 million compared with $32.8 million in the prior year. Loss before income taxes was $5,396,000 compared to $2,654,000 a year ago. Net loss was $5,400,000 or $0.10 per basic and diluted share compared to $2,500,000 or $0.04 per basic and diluted share a year ago. For the year, the company reported revenue of $288,720,000 compared to $247,084,000 a year ago. Operating loss was $12,297,000 compared to $29,135,000 a year ago. Loss before income taxes was $51,358,000 compared to $44,874,000 a year ago. Net loss was $51,500,000 or $0.93 per basic and diluted share compared to $44,974,000 or $0.83 per basic and diluted share a year ago. The main difference between full year 2014 net loss and $12.3 million operating loss was the $39.1 million of net interest expense, which included the loss on extinguishment of 3.75% convertible notes in addition to interest on outstanding 2% convertible notes. For the year ending December 31, 2015, the company expects revenue to be in the range of $305 million to $320 million. The majority of the growth is expected in the back half of the year as gain traction from the new team and commercial initiatives. For the first quarter of 2015, the company expects revenue to be in the range of $67 million to $69 million, driven by a reduction of inventory levels by international partners. This reduction will be partially offset by the expected increase in revenue from drug delivery business.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PODD:US $30.72 USD +0.11

PODD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $48.32 USD -0.14
Eli Lilly & Co $71.58 USD -0.82
Smiths Group PLC 1,135 GBp -7.00
Takeda Pharmaceutical Co Ltd ¥6,247 JPY -52.00
Tandem Diabetes Care Inc $13.68 USD -0.26
View Industry Companies
 

Industry Analysis

PODD

Industry Average

Valuation PODD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.0x
Price/Book 20.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSULET CORP, please visit www.insulet.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.